CAMP and cancer: Co-administration of LL-37, cleaved form of 18 kDa human cathelicidin protein (hCAP18), with CpG-ODN, generates synergistic effects on anticancer activity and increases survival in MOSEC/luc cancer-bearing mice compared with respective treatment with each drug [193].